Abstract
In article number 2002143 by Qiang-Zhe Zhang, Lu-Yuan Li, and co-workers, a novel MMP9-catalyzed charge reversal nanoparticle (O-NP) is developed for theranostic agents in cancer diagnosis and therapy. The O-NP nanohybrid successfully performs preferential accumulation and enhances the endocytosis in MMP9-expressing xenografted tumors by charge reversal from negative to positive in mouse models, which improves the sensitivity of diagnosis agents and the anti-tumor effects of drugs in vivo by overcoming their low solubility and/or nonspecific enrichment.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
